PE-22-28
Also known as: PE 22-28, spadin analog (7 amino-acid)
Endogenous peptide analog / TREK-1 channel inhibitor
What it is
PE-22-28 is a small peptide studied in animal models for its antidepressant effects, working by blocking a potassium channel in the brain that influences mood and neurogenesis. It is more potent than related compounds in early lab tests. No FDA-approved use; evidence comes from animal models only.
The scientific side
PE-22-28 is a 7 amino-acid peptide derived from the study of blood degradation products of spadin (PE 12-28). It specifically inhibits the TREK-1 potassium channel with an IC50 of 0.12 nM (versus 40–60 nM for spadin), as demonstrated in hTREK-1/HEK cells using patch-clamp technique. By blocking TREK-1, PE-22-28 exerts antidepressant-like effects, promotes neurogenesis, and enhances synaptogenesis (measured by increased PSD-95 expression) in mouse cortical neurons. Its action duration is up to 23 hours, compared to 7 hours for spadin.
Class: Endogenous peptide analog / TREK-1 channel inhibitor
Administration & storage
- Administration
- Route of administration not explicitly stated in the reviewed abstract (PMID: 28955242)
- Storage
- No storage conditions for PE-22-28 are described in the reviewed abstract.
- Cautions
- No human pharmacokinetic or safety data are available in the reviewed literature — clinical safety profile is unknown.,PE-22-28 is a research-stage peptide; its tolerability, toxicity, and adverse effect profile in humans have not been described in the reviewed abstract.,Modifications to the N- or C-terminal ends of PE-22-28 can abolish TREK-1 channel activity, suggesting that peptide purity and structural integrity are critical.,Sterile technique is essential for any injectable research compound to prevent contamination.
Legal & regulatory status
Not stated in reviewed literature — requires manual verification
Not stated in reviewed literature — requires manual verification
Not stated in reviewed literature — requires manual verification
What it's studied for
- Antidepressant activity Animal studies only
- PE-22-28 reduced immobility time in the forced swimming test and reduced latency to eat in the novelty suppressed feeding test after 4-day sub-chronic treatment in mice, demonstrating antidepressant-like behavioral effects. PMID 28955242 Djillani A et al., Frontiers in Pharmacology, 2017
- TREK-1 channel inhibition In vitro only
- PE-22-28 displayed an IC50 of 0.12 nM for TREK-1 inhibition in hTREK-1/HEK cells via patch-clamp, showing better specificity and affinity than spadin (IC50 40–60 nM). PMID 28955242 Djillani A et al., Frontiers in Pharmacology, 2017
- Neurogenesis induction Animal studies only
- PE-22-28 and its analogs induced neurogenesis after only a 4-day treatment in mice, with a prominent effect observed for the G/A-PE 22-28 derivative. PMID 28955242 Djillani A et al., Frontiers in Pharmacology, 2017
- Synaptogenesis enhancement In vitro only
- On mouse cortical neurons, PE-22-28 and its derivatives enhanced synaptogenesis as measured by increased PSD-95 expression levels. PMID 28955242 Djillani A et al., Frontiers in Pharmacology, 2017
Safety signals
- No adverse effects or safety signals are explicitly reported in the reviewed abstract for PE-22-28. The parent compound spadin was described as having a delayed onset and serious adverse effects as a class concern for antidepressants generally, but no specific safety signals were attributed to PE-22-28 itself. PMID 28955242
Contraindications
- No contraindications for PE-22-28 are stated in the reviewed literature. PMID 28955242
Protocol
No community dose for PE-22-28 on record yet.
All studies (1)
- PMID 28955242 Animal studies only
Antidepressant activity
Frequently asked
What is PE-22-28 and how does it work?
PE-22-28 is a 7 amino-acid peptide analog of spadin (PE 12-28), designed from spadin's blood degradation products. It works by specifically inhibiting the TREK-1 potassium channel, with an IC50 of 0.12 nM in hTREK-1/HEK cells — making it substantially more potent than spadin (IC50 40–60 nM). This inhibition is associated with antidepressant-like effects, neurogenesis, and synaptogenesis in preclinical models.
Has PE-22-28 been tested in humans?
Based on the available literature I've reviewed, PE-22-28 has only been studied in animal (mouse) behavioral models and in vitro (hTREK-1/HEK cell) systems. No human clinical trials or human pharmacokinetic data are described in the reviewed abstract.
What dose of PE-22-28 should I take?
I'm not a medical professional and can't recommend a protocol for you specifically. What research has shown: PE-22-28 has only been studied in preclinical (mouse and cell) models. The reviewed abstract describes a 4-day sub-chronic treatment in mice but does not provide explicit numeric dose or route information applicable to humans.
How long does PE-22-28 stay active compared to spadin?
According to the reviewed study, PE-22-28 and its analogs have an action duration of up to 23 hours, compared to approximately 7 hours for the parent compound spadin. This represents a major improvement in stability and bioavailability.
Can PE-22-28 be used to treat depression?
I can't suggest treatments for medical conditions. Please speak with a licensed healthcare provider. What the preclinical research shows: in mouse models, PE-22-28 reduced immobility time in the forced swimming test and reduced latency to eat in the novelty suppressed feeding test after 4-day sub-chronic treatment, suggesting antidepressant-like activity. No human clinical data are available in the reviewed literature.
What is the IC50 of PE-22-28 for TREK-1?
In hTREK-1/HEK cells using the patch-clamp technique, PE-22-28 demonstrated an IC50 of 0.12 nM for TREK-1 inhibition, compared to 40–60 nM for spadin. This indicates substantially greater potency and specificity for the TREK-1 channel.
Can I stack PE-22-28 with an antidepressant?
I can't recommend combining compounds — that's a prescribing decision. Here's what has been studied individually: PE-22-28 has shown antidepressant-like activity in preclinical mouse models via TREK-1 inhibition. No combination studies are described in the reviewed literature.
Where can I buy PE-22-28?
I don't recommend vendors or sources. Please consult a licensed provider.
Does PE-22-28 cause neurogenesis?
In preclinical mouse studies, PE-22-28 and its analogs induced neurogenesis after only a 4-day treatment period. A particularly prominent neurogenic effect was observed with the G/A-PE 22-28 derivative. These are animal findings; no human neurogenesis data are available in the reviewed literature.
What are the side effects of PE-22-28?
I don't have reliable study data on that specific question. The reviewed abstract does not report adverse effects or safety signals for PE-22-28. No human safety data exist in the reviewed literature. I won't guess — please consult a licensed provider or peer-reviewed literature directly.